1. Stein LD. Human genome: end of the beginning. Nature 2004; 431(7011): 915–916.
2. Taft RJ, Pang KC, Mercer TR et al. Non-coding RNAs: regulators of disease. J Pathol 2010; 220(2): 126–139.
3. Mattick JS. Non-coding RNAs: the architects of eukaryotic complexity. EMBO Rep 2001; 2: 986–991.
4. Zhang R, Zhang L, Yu W. Genome-wide expression of non-coding RNA and global chromatin modification. Acta Biochim Biophys Sin (Shanghai) 2012; 44(1): 40–47.
5. Pagano A, Castelnuovo M, Tortelli F et al. New small nuclear RNA gene-like transcriptional units as sources of regulatory transcripts. PLoS Genet 2007; 3(2): e1.
6. Guttman M, Amit I, Garber M et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 2009; 458(7235): 223–237.
7. Costa FF. Non-coding RNAs: Meet thy masters. Bioessays 2010; 32(7): 599–608.
8. Chen Y, Song Y, Wang Z et al. Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance. J Gastrointest Surg 2010; 14(7): 1170–1179.
9. Lipovich L, Johnson R, Lin CY. MacroRNA underdogs in a mikroRNA world: evolutionary, regulatory, and biomedical significance of mammalian long non-protein-coding RNA. Biochim Biophys Acta 2010; 1799(9): 597–615.
10. Tripathi V, Ellis JD, Shen Z et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell 2010; 39(6): 925–938.
11. Gupta RA, Shah N, Wang KC et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010; 464(7291): 1071–1076.
12. Orom UA, Derrien T, Beringer M et al. Long noncoding RNAs with enhancer-like function in human cells. Cell 2010; 143(1): 46–58.
13. Iacoangeli A, Lin Y, Morley EJ et al. BC200 RNA in invasive and preinvasive breast cancer. Carcinogenesis 2004; 25(11): 2125–2133.
14. Mattick JS, Amaral PP, Dinger ME et al. RNA regulation of epigenetic processes. Bioessays 2009; 31(1): 51–59.
15. Ishii N, Ozaki K, Sato H et al. Identification of a novel non-coding RNA, MIAT, that confers risk of myocardial infarction. J Hum Genet 2006; 51(12): 1087–1099.
16. Faghihi MA, Modarresi F, Khalil AM et al. Expression of a noncoding RNA is elevated in Alzheimer’s disease and drives rapid feed-forward regulation of beta-secretase. Nat Med 2008; 14(7): 723–730.
17. Sana J, Faltejskova P, Svoboda M et al. Novel classes of non-coding RNAs and cancer. J Transl Med 2012; 10(1): 103.
18. Costa FF. Non-coding RNAs: new players in eukaryotic biology. Gene 2005; 357(2): 83–94.
19. Okamura K, Chung WJ, Ruby JG et al. The Drosophila hairpin RNA pathway generates endogenous short interfering RNAs. Nature 2008; 453(7196): 803–806.
20. Rinn JL, Kertesz M, Wang JK et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 2007; 129(7): 1311–1323.
21. Khalil AM, Guttman M, Huarte M et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci U S A 2009; 106(28): 11667–11672.
22. Brannan CI, Dees EC, Ingram RS et al. The product of the H19 gene may function as an RNA. Mol Cell Biol 1990; 10(1): 28–36.
23. Gabory A, Jammes H, Dandolo L. The H19 locus: role of an imprinted non-coding RNA in growth and development. Bioessays 2010; 32(6): 473–480.
24. Hibi K, Nakamura H, Hirai A et al. Loss of H19 imprinting in esophageal cancer. Cancer Res 1996; 56(3): 480–482.
25. Tsai MC, Manor O, Wan Y et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 2010; 329(5992): 689–693.
26. Yang Z, Zhou L, Wu LM et al. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann Surg Oncol 2011; 18(5): 1243–1250.
27. Louro R, Smirnova AS, Verjovski-Almeida S. Long intronic noncoding RNA transcription: expression noise or expression choice? Genomics 2009; 93(4): 291–298.
28. Louro R, Nakaya HI, Amaral PP et al. Androgen responsive intronic non-coding RNAs. BMC Biol 2007; 5: 4.
29. Cawley S, Bekiranov S, Ng HH et al. Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell 2004; 116(4): 499–509.
30. Nakaya HI, Amaral PP, Louro R et al. Genome mapping and expression analyses of human intronic noncoding RNAs reveal tissue-specific patterns and enrichment in genes related to regulation of transcription. Genome Biol 2007; 8(3): R43.
31. Dinger ME, Amaral PP, Mercer TR et al. Long noncoding RNAs in mouse embryonic stem cell pluripotency and differentiation. Genome Res 2008; 18(9): 1433–1445.
32. Kravchenko JE, Rogozin IB, Koonin EV et al. Transcription of mammalian messenger RNAs by a nuclear RNA polymerase of mitochondrial origin. Nature 2005; 436(7051): 735–739.
33. Li SC, Tang P, Lin WC. Intronic mikroRNA: discovery and biological implications. DNA Cell Biol 2007; 26(4): 195–207.
34. Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human mikroRNAs. Nat Struct Mol Biol 2006; 13(12): 1097–1101.
35. Massone S, Vassallo I, Castelnuovo M et al. RNA polymerase III drives alternative splicing of the potassium channel-interacting protein contributing to brain complexity and neurodegeneration. J Cell Biol 2011; 193(5): 851–866.
36. Massone S, Vassallo I, Fiorino G et al. 17A, a novel non-coding RNA, regulates GABA B alternative splicing and signaling in response to inflammatory stimuli and in Alzheimer disease. Neurobiol Dis 2011; 41(2): 308–317.
37. Louro R, El-Jundi T, Nakaya HI et al. Conserved tissue expression signatures of intronic noncoding RNAs transcribed from human and mouse loci. Genomics 2008; 92(1): 18–25.
38. Rearick D, Prakash A, McSweeny A et al. Critical association of ncRNA with introns. Nucleic Acids Res 2011; 39(6): 2357–2366.
39. Mercer TR, Dinger ME, Sunkin SM et al. Specific expression of long noncoding RNAs in the mouse brain. Proc Natl Acad Sci U S A 2008; 105(2): 716–721.
40. Katayama S, Tomaru Y, Kasukawa T et al. Antisense transcription in the mammalian transcriptome. Science 2005; 309(5740): 1564–1566.
41. Filipowicz W, Pogacic V. Biogenesis of small nucleolar ribonucleoproteins. Curr Opin Cell Biol 2002; 14(3): 319–327.
42. Hirose T, Ideue T, Nagai M et al. A spliceosomal intron binding protein, IBP160, links position-dependent assembly of intron-encoded box C/D snoRNP to pre-mRNA splicing. Mol Cell 2006; 23(5): 673–684.
43. Heo JB, Sung S. Vernalization-mediated epigenetic silencing by a long intronic noncoding RNA. Science 2011; 331(6013): 76–79.
44. Tahira AC, Kubrusly MS, Faria MF et al. Long noncoding intronic RNAs are differentially expressed in primary and metastatic pancreatic cancer. Mol Cancer 2011; 10: 141.
45. Isken O, Maquat LE. Telomeric RNAs as a novel player in telomeric integrity. F1000 Biol Rep 2009; 1: 90.
46. Azzalin CM, Reichenbach P, Khoriauli L et al. Telomeric repeat containing RNA and RNA surveillance factors at mammalian chromosome ends. Science 2007; 318(5851): 798–801.
47. Schoeftner S, Blasco MA. Developmentally regulated transcription of mammalian telomeres by DNA-dependent RNA polymerase II. Nat Cell Biol 2008; 10(2): 228–236.
48. Schoeftner S, Blasco MA. A ‚higher order‘ of telomere regulation: telomere heterochromatin and telomeric RNAs. EMBO J 2009; 28(16): 2323–2336.
49. Luke B, Panza A, Redon S et al. The Rat1p 5‘ to 3‘ exonuclease degrades telomeric repeat-containing RNA and promotes telomere elongation in Saccharomyces cerevisiae. Mol Cell 2008; 32(4): 465–477.
50. Sampl S, Pramhas S, Stern C et al. Expression of Telomeres in Astrocytoma WHO Grade 2 to 4: TERRA Level Correlates with Telomere Length, Telomerase Activity, and Advanced Clinical Grade. Transl Oncol 2012; 5(1): 56–65.
51. Schoeftner S, Blasco MA. Chromatin regulation and non-coding RNAs at mammalian telomeres. Semin Cell Dev Biol 2010; 21(2): 186–193.
52. Ulveling D, Francastel C, Hube F. When one is better than two: RNA with dual functions. Biochimie 2011; 93(4): 633–644.
53. Lanz RB, McKenna NJ, Onate SA et al. A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell 1999; 97(1): 17–27.
54. Kawashima H, Takano H, Sugita S et al. A novel steroid receptor co-activator protein (SRAP) as an alternative form of steroid receptor RNA-activator gene: expression in prostate cancer cells and enhancement of androgen receptor activity. Biochem J 2003; 369(Pt 1): 163–171.
55. Chooniedass-Kothari S, Emberley E, Hamedani MK, et al. The steroid receptor RNA activator is the first functional RNA encoding a protein. FEBS Lett 2004; 566 (1–3): 43–47.
56. Xu K, Liang X, Cui D et al. miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells. Mol Carcinog 2011. [Epub ahead of print].
57. Hussein-Fikret S, Fuller PJ. Expression of nuclear receptor coregulators in ovarian stromal and epithelial tumours. Mol Cell Endocrinol 2005; 229(1–2): 149–160.
58. Lanz RB, Chua SS, Barron N et al. Steroid receptor RNA activator stimulates proliferation as well as apoptosis in vivo. Mol Cell Biol 2003; 23(20): 7163–7176.
59. Leygue E, Dotzlaw H, Watson PH et al. Expression of the steroid receptor RNA activator in human breast tumors. Cancer Res 1999; 59(17): 4190–4193.
60. Harrison PM, Zheng D, Zhang Z et al. Transcribed processed pseudogenes in the human genome: an intermediate form of expressed retrosequence lacking protein-coding ability. Nucleic Acids Res 2005; 33(8): 2374–2383.
61. Pink RC, Wicks K, Caley DP et al. Pseudogenes: pseudo-functional or key regulators in health and disease? RNA 2011; 17(5): 792–798.
62. Esnault C, Maestre J, Heidmann T. Human LINE retrotransposons generate processed pseudogenes. Nat Genet 2000; 24(4): 363–367.
63. Terai G, Yoshizawa A, Okida H et al. Discovery of short pseudogenes derived from messenger RNAs. Nucleic Acids Res 2010; 38(4): 1163–1171.
64. Devor EJ. Primate mikroRNAs miR-220 and miR-492 lie within processed pseudogenes. J Hered 2006; 97(2): 186–190.
65. Han YJ, Ma SF, Yourek G et al. A transcribed pseudogene of MYLK promotes cell proliferation. FASEB J 2011; 25(7): 2305–2312.
66. Lu W, Zhou D, Glusman G et al. KLK31P is a novel androgen regulated and transcribed pseudogene of kallikreins that is expressed at lower levels in prostate cancer cells than in normal prostate cells. Prostate 2006; 66(9): 936–944.
67. Bejerano G, Pheasant M, Makunin I et al. Ultraconserved elements in the human genome. Science 2004; 304(5675): 1321–1325.
68. Nobrega MA, Ovcharenko I, Afzal V et al. Scanning human gene deserts for long-range enhancers. Science 2003; 302(5 644): 413.
69. Lujambio A, Portela A, Liz J et al. CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer. Oncogene 2010; 29(48): 6390–63401.
70. Calin GA, Liu CG, Ferracin M et al. Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell 2007; 12(3): 215–229.
71. Scaruffi P, Stigliani S, Moretti S et al. Transcribed-Ultra Conserved Region expression is associated with outcome in high-risk neuroblastoma. BMC Cancer 2009; 9: 441.
72. Sana J, Hankeova S, Svoboda M et al. Expression levels of transcribed ultraconserved regions uc.73 and uc.388 are altered in colorectal cancer. Oncology 2012; 82(2): 114–118.
73. Mestdagh P, Fredlund E, Pattyn F et al. An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours. Oncogene 2010; 29(24): 3583–3592.
74. Catucci I, Verderio P, Pizzamiglio S et al. SNPs in ultraconserved elements and familial breast cancer risk. Carcinogenesis 2009; 30(3): 544–545; author reply 6.
75. Yang R, Frank B, Hemminki K et al. SNPs in ultraconserved elements and familial breast cancer risk. Carcinogenesis 2008; 29(2): 351–355.
76. Ji P, Diederichs S, Wang W et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 2003; 22(39): 8031–8041.
77. Lin R, Maeda S, Liu C et al. A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene 2007; 26(6): 851–858.
78. Davis IJ, Hsi BL, Arroyo JD et al. Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation. Proc Natl Acad Sci U S A 2003; 100(10): 6051–6056.
79. Guo F, Li Y, Liu Y et al. Inhibition of metastasis-associated lung adenocarcinoma transcript 1 in CaSki human cervical cancer cells suppresses cell proliferation and invasion. Acta Biochim Biophys Sin (Shanghai) 2010; 42(3): 224–229.
80. Fellenberg J, Bernd L, Delling G et al. Prognostic significance of drug-regulated genes in high-grade osteosarcoma. Mod Pathol 2007; 20(10): 1085–1094.
81. Koshimizu TA, Fujiwara Y, Sakai N et al. Oxytocin stimulates expression of a noncoding RNA tumor marker in a human neuroblastoma cell line. Life Sci 2010; 86 (11–12): 455–460.
82. Panzitt K, Tschernatsch MM, Guelly C et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 2007; 132(1): 330–342.
83. Matouk IJ, Abbasi I, Hochberg A et al. Highly upregulated in liver cancer noncoding RNA is overexpressed in hepatic colorectal metastasis. Eur J Gastroenterol Hepatol 2009; 21(6): 688–692.
84. Chen W, Bocker W, Brosius J et al. Expression of neural BC200 RNA in human tumours. J Pathol 1997; 183(3): 345–351.
85. Berteaux N, Lottin S, Adriaenssens E et al. Hormonal regulation of H19 gene expression in prostate epithelial cells. J Endocrinol 2004; 183(1): 69–78.
86. Eis PS, Tam W, Sun L et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A 2005; 102(10): 3627–3632.
87. Chung S, Nakagawa H, Uemura M et al. Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci 2011; 102(1): 245–252.
88. Pasic I, Shlien A, Durbin AD et al. Recurrent focal copy-number changes and loss of heterozygosity implicate two noncoding RNAs and one tumor suppressor gene at chromosome 3q13.31 in osteosarcoma. Cancer Res 2010; 70(1): 160–171.
89. Petrovics G, Zhang W, Makarem M et al. Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene 2004; 23(2): 605–611.
90. Srikantan V, Zou Z, Petrovics G et al. PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proc Natl Acad Sci U S A 2000; 97(22): 12216–12221.
91. Fu X, Ravindranath L, Tran N et al. Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1. DNA Cell Biol 2006; 25(3): 135–141.
92. Wang XS, Zhang Z, Wang HC et al. Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma. Clin Cancer Res 2006; 12(16): 4851–4858.
93. Wang F, Li X, Xie X et al. UCA1, a non-protein-coding RNA up-regulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion. FEBS Lett 2008; 582(13): 1919–1927.
94. Bussemakers MJ, van Bokhoven A, Verhaegh GW et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59(23): 5975–5979.
95. de Kok JB, Verhaegh GW, Roelofs RW et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002; 62(9): 2695–2698.
96. Korneev SA, Korneeva EI, Lagarkova MA et al. Novel noncoding antisense RNA transcribed from human anti-NOS2A locus is differentially regulated during neuronal differentiation of embryonic stem cells. RNA 2008; 14(10): 2030–2037.
97. Braconi C, Valeri N, Kogure T et al. Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. Proc Natl Acad Sci U S A 2011; 108(2): 786–791.
98. Yu W, Gius D, Onyango P et al. Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature 2008; 451(7175): 202–206.
99. Folkersen L, Kyriakou T, Goel A et al. Relationship between CAD risk genotype in the chromosome 9p21 locus and gene expression. Identification of eight new ANRIL splice variants. PLoS One 2009; 4(11): e7677.
100. Yap KL, Li S, Munoz-Cabello AM et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell 2010; 38(5): 662–674.
101. Pasmant E, Laurendeau I, Heron D et al. Characterization of a germ-line deletion, including the entire INK4//ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res 2007; 67(8): 3963–3969.
102. Miyoshi N, Wagatsuma H, Wakana S et al. Identification of an imprinted gene, Meg3/Gtl2 and its human homologue MEG3, first mapped on mouse distal chromosome 12 and human chromosome 14q. Genes Cells 2000; 5(3): 211–220.
103. Zhang X, Zhou Y, Mehta KR et al. A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab 2003; 88(11): 5119–5126.
104. Zhang X, Rice K, Wang Y et al. Maternally expressed gene 3 (MEG3) noncoding ribonucleic acid: isoform structure, expression, and functions. Endocrinology 2010; 151(3): 939–947.
105. Mourtada-Maarabouni M, Pickard MR, Hedge VL et al. GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene 2009; 28(2): 195–208.
106. Chooniedass-Kothari S, Hamedani MK, Troup S et al. The steroid receptor RNA activator protein is expressed in breast tumor tissues. Int J Cancer 2006; 118(4): 1054–1059.
107. Poliseno L, Salmena L, Zhang J et al. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 2010; 465(7301): 1033–1038.
108. Alimonti A, Carracedo A, Clohessy JG et al. Subtle variations in Pten dose determine cancer susceptibility. Nat Genet 2010; 42(5): 454–458.
109. Zhu Y, Yu M, Li Z et al. ncRAN, a newly identified long noncoding RNA, enhances human bladder tumor growth, invasion, and survival. Urology 2011; 77(2): 510e1–510e5.
110. Yu M, Ohira M, Li Y et al. High expression of ncRAN, a novel non-coding RNA mapped to chromosome 17q25.1, is associated with poor prognosis in neuroblastoma. Int J Oncol 2009; 34(4): 931–938.
111. Silva JM, Boczek NJ, Berres MW et al. LSINCT5 is over expressed in breast and ovarian cancer and affects cellular proliferation. RNA Biol 2011; 8(3): 496–505.
112. Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer 2011; 10: 38.